- Home
- PRHI vs LYRA Comparison
PRHI vs LYRA Comparison
Compare PRHI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRHI
- LYRA
- Stock Information
- Founded
- PRHI 2009
- LYRA 2005
- Country
- PRHI United States
- LYRA United States
- Employees
- PRHI N/A
- LYRA N/A
- Industry
- PRHI Property-Casualty Insurers
- LYRA Medical/Dental Instruments
- Sector
- PRHI Finance
- LYRA Health Care
- Exchange
- PRHI Nasdaq
- LYRA Nasdaq
- Market Cap
- PRHI 13.7M
- LYRA 11.3M
- IPO Year
- PRHI N/A
- LYRA 2020
- Fundamental
- Price
- PRHI $1.45
- LYRA $5.94
- Analyst Decision
- PRHI
- LYRA Hold
- Analyst Count
- PRHI 0
- LYRA 1
- Target Price
- PRHI N/A
- LYRA $16.00
- AVG Volume (30 Days)
- PRHI 2.1M
- LYRA 51.1K
- Earning Date
- PRHI 11-12-2025
- LYRA 11-07-2025
- Dividend Yield
- PRHI N/A
- LYRA N/A
- EPS Growth
- PRHI N/A
- LYRA N/A
- EPS
- PRHI 2.45
- LYRA N/A
- Revenue
- PRHI $52,654,000.00
- LYRA $770,000.00
- Revenue This Year
- PRHI $25.91
- LYRA N/A
- Revenue Next Year
- PRHI N/A
- LYRA $106.28
- P/E Ratio
- PRHI $0.60
- LYRA N/A
- Revenue Growth
- PRHI N/A
- LYRA N/A
- 52 Week Low
- PRHI $0.42
- LYRA $3.81
- 52 Week High
- PRHI $2.83
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- PRHI N/A
- LYRA 34.62
- Support Level
- PRHI N/A
- LYRA $6.25
- Resistance Level
- PRHI N/A
- LYRA $7.30
- Average True Range (ATR)
- PRHI 0.00
- LYRA 0.52
- MACD
- PRHI 0.00
- LYRA -0.16
- Stochastic Oscillator
- PRHI 0.00
- LYRA 0.46
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.